ArticleG3 (Bethesda, Md.)2012
Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype.
Article in G3 (Bethesda, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Review
- Contribution of Keratinocytes in Skin Cancer Initiation and Progression.International journal of molecular sciences · 2024Review
- Biomarkers in Cutaneous Keratinocyte Carcinomas.Dermatology and therapy · 2024Review
- MicroRNA Signatures Associated with Basal Cell Carcinoma Subtypes.JID innovations : skin science from molecules to population health · 2024Article
- Does the histopathological subtype of primary basal cell carcinoma predict the subtype of secondary tumours? What role do genetic mutations play?Skin health and disease · 2023Article
- Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.Journal for immunotherapy of cancer · 2022Article
- Review
- Novel alterations in IFT172 and KIFAP3 may induce basal cell carcinoma.Orphanet journal of rare diseases · 2021Article
- IsomiR_Window: a system for analyzing small-RNA-seq data in an integrative and user-friendly manner.BMC bioinformatics · 2021Article
- Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2020Review
- Basal Cell Carcinoma: A Comprehensive Review.International journal of molecular sciences · 2020Review
- Importance of microRNAs in Skin Oncogenesis and Their Suitability as Agents and Targets for Topical Therapy.Skin pharmacology and physiology · 2020Review
- Cross-Talk between Wnt and Hh Signaling Pathways in the Pathology of Basal Cell Carcinoma.International journal of environmental research and public health · 2018Review
- Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.Molecular carcinogenesis · 2017Review
- Non-coding RNAs in skin cancers: An update.Non-coding RNA research · 2016Review
- MicroRNAs and p63 in epithelial stemness.Cell death and differentiation · 2015Article
- Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies.PloS one · 2013Article
- UVA and UVB irradiation differentially regulate microRNA expression in human primary keratinocytes.PloS one · 2013Article
- miRNA: The Next Frontier in Dermatology Research and Therapeutics.Indian journal of dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Basal cell carcinomas (BCCs) are the most common cancers in the United States. The histologic appearance distinguishes several subtypes, each of which can have a different biologic behavior. In this study, global miRNA expression was quantified by high-throughput sequencing in nodular BCCs, a subtype that is slow growing, and infiltrative BCCs, aggressive tumors that extend through the dermis and invade structures such as cutaneous nerves. Principal components analysis correctly classified seven of eight infiltrative tumors on the basis of miRNA expression. The remaining tumor, on pathology review, contained a mixture of nodular and infiltrative elements. Nodular tumors did not cluster tightly, likely reflecting broader histopathologic diversity in this class, but trended toward forming a group separate from infiltrative BCCs. Quantitative polymerase chain reaction assays were developed for six of the miRNAs that showed significant differences between the BCC subtypes, and five of these six were validated in a replication set of four infiltrative and three nodular tumors. The expression level of miR-183, a miRNA that inhibits invasion and metastasis in several types of malignancies, was consistently lower in infiltrative than nodular tumors and could be one element underlying the difference in invasiveness. These results represent the first miRNA profiling study in BCCs and demonstrate that miRNA gene expression may be involved in tumor pathogenesis and particularly in determining the aggressiveness of these malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.